Literature DB >> 25489961

Perceptions of patients with inflammatory bowel diseases on biobanking.

Millie D Long1, R Jean Cadigan, Suzanne F Cook, Kaaren Haldeman, Kriste Kuczynski, Robert S Sandler, Christopher F Martin, Wenli Chen, Michael D Kappelman.   

Abstract

BACKGROUND: Little is known about beliefs, understanding, and perceptions of biobanking among patients with inflammatory bowel diseases. We aimed to further understand perceptions of biobanking in the inflammatory bowel disease community.
METHODS: Subjects were recruited to participate in a 1:1 telephone interview on their perceptions of the risks and benefits of contributing specimens for research. These interviews informed a survey instrument evaluating perceptions of biobanking within Crohn's and Colitis Foundation of America Partners cohort. We used descriptive statistics to summarize participant responses, and bivariate statistics to compare willingness to participate in biobanking by disease and demographic factors.
RESULTS: A total of 26 interviews were conducted. Various themes emerged from the interviews and aided in the development of the survey instrument. Concerns focused on storage, loss of confidentiality, outside uses, and life insurance discrimination. A total of 1007 individuals completed the survey. Overall, 397 (39.4%) reported that they would definitely donate samples, 568 (56.4%) would probably donate, 36 (3.6%) probably not, and 6 (0.6%) would definitely not donate. No significant differences in willingness to donate samples were seen for Crohn's disease versus ulcerative colitis (P = 0.25) or for remission versus active disease (P = 0.14). For sample-type preference, 956 (89.6%) would donate blood, 997 (93.5%) saliva, and 822 (77.1%) stool.
CONCLUSIONS: Majorities of patients with inflammatory bowel disease demonstrated willingness to donate specimens for biobanking, albeit with concerns. Addressing these concerns will enhance participation and engagement and create greater alignment between the desires of research participants and the governance structure and operating policies of biobanks.

Entities:  

Mesh:

Year:  2015        PMID: 25489961      PMCID: PMC4573563          DOI: 10.1097/MIB.0000000000000263

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  19 in total

1.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

2.  What is a biobank? Differing definitions among biobank stakeholders.

Authors:  D M Shaw; B S Elger; F Colledge
Journal:  Clin Genet       Date:  2013-10-16       Impact factor: 4.438

3.  Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners).

Authors:  Rachel L Randell; Millie D Long; Suzanne F Cook; Christina E D Wrennall; Wenli Chen; Christopher F Martin; Kristen Anton; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2014-03       Impact factor: 5.325

Review 4.  Environmental triggers for inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan
Journal:  Curr Gastroenterol Rep       Date:  2013-01

5.  Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.

Authors:  Lee A Denson; Millie D Long; Dermot P B McGovern; Subra Kugathasan; Gary D Wu; Vincent B Young; Theresa T Pizarro; Edwin F de Zoeten; Thaddeus S Stappenbeck; Scott E Plevy; Clara Abraham; Asma Nusrat; Christian Jobin; Declan F McCole; Corey A Siegel; Peter D R Higgins; Hans H Herfarth; Jeffrey Hyams; William J Sandborn; Edward V Loftus; Michael D Kappelman; James D Lewis; Charles A Parkos; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

6.  Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis.

Authors:  Ashwin N Ananthakrishnan; Millie D Long; Christopher F Martin; Robert S Sandler; Michael D Kappelman
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-01       Impact factor: 11.382

7.  Cancer patient perceptions about biobanking and preferred timing of consent.

Authors:  Kathryn L Braun; Joann U Tsark; Amy Powers; Kristen Croom; Robert Kim; Francine C Gachupin; Paul Morris
Journal:  Biopreserv Biobank       Date:  2014-04       Impact factor: 2.300

8.  Biobanking for research: a survey of patient population attitudes and understanding.

Authors:  Alanna Kulchak Rahm; Michelle Wrenn; Nikki M Carroll; Heather Spencer Feigelson
Journal:  J Community Genet       Date:  2013-04-20

9.  Risk factors for depression in the elderly inflammatory bowel disease population.

Authors:  Millie D Long; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler
Journal:  J Crohns Colitis       Date:  2013-08-06       Impact factor: 9.071

10.  Characterizing biobank organizations in the U.S.: results from a national survey.

Authors:  Gail E Henderson; R Jean Cadigan; Teresa P Edwards; Ian Conlon; Anders G Nelson; James P Evans; Arlene M Davis; Catherine Zimmer; Bryan J Weiner
Journal:  Genome Med       Date:  2013-01-25       Impact factor: 11.117

View more
  8 in total

1.  Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn's and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners).

Authors:  Arlene E Chung; Robert S Sandler; Millie D Long; Sean Ahrens; Jessica L Burris; Christopher F Martin; Kristen Anton; Amber Robb; Thomas P Caruso; Elizabeth L Jaeger; Wenli Chen; Marshall Clark; Kelly Myers; Angela Dobes; Michael D Kappelman
Journal:  J Am Med Inform Assoc       Date:  2016-01-28       Impact factor: 4.497

2.  "Forward-Thinking" in U.S. Biobanking.

Authors:  R Jean Cadigan; Teresa P Edwards; Dragana Lassiter; Arlene M Davis; Gail E Henderson
Journal:  Genet Test Mol Biomarkers       Date:  2017-01-24

3.  Clinical Trial Participants' Views of the Risks and Benefits of Data Sharing.

Authors:  Michelle M Mello; Van Lieou; Steven N Goodman
Journal:  N Engl J Med       Date:  2018-06-07       Impact factor: 91.245

4.  Feasibility of salivary DNA collection in a population-based case-control study: a pilot study of pediatric Crohn's disease.

Authors:  Michael D Kappelman; Aksel Lange; Rachel L Randell; Patricia V Basta; Robert S Sandler; Kristina Laugesen; Anna Byrjalsen; Tina Christensen; Trine Frøslev; Rune Erichsen
Journal:  Clin Epidemiol       Date:  2018-02-28       Impact factor: 4.790

5.  Cancer Patient Perspectives on Sharing of Medical Records and Mobile Device Data for Research Purposes.

Authors:  Elizabeth F Franklin; Helen M Nichols; Linda House; Joanne Buzaglo; Kim Thiboldeaux
Journal:  J Patient Exp       Date:  2020-05-08

6.  Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions.

Authors:  W Benjamin Nowell; Peter A Merkel; Robert N McBurney; Kalen Young; Shilpa Venkatachalam; Dianne G Shaw; Angela Dobes; Emily Cerciello; Laura Kolaczkowski; Jeffrey R Curtis; Michael D Kappelman
Journal:  Patient       Date:  2021-04-27       Impact factor: 3.883

7.  Collecting Biospecimens From an Internet-Based Prospective Cohort Study of Inflammatory Bowel Disease (CCFA Partners): A Feasibility Study.

Authors:  Rachel L Randell; Ajay S Gulati; Suzanne F Cook; Christopher F Martin; Wenli Chen; Elizabeth L Jaeger; Alexi A Schoenborn; Patricia V Basta; Hendrik Dejong; Jingchun Luo; Marisa Gallant; Robert S Sandler; Millie D Long; Michael D Kappelman
Journal:  JMIR Res Protoc       Date:  2016-01-05

8.  A systematic literature review of individuals' perspectives on broad consent and data sharing in the United States.

Authors:  Nanibaa' A Garrison; Nila A Sathe; Armand H Matheny Antommaria; Ingrid A Holm; Saskia C Sanderson; Maureen E Smith; Melissa L McPheeters; Ellen W Clayton
Journal:  Genet Med       Date:  2015-11-19       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.